IP Library › Granted Patent US 9,051,312
Granted Patent B2
US 9,051,312 · App. 14/472,794 · Granted Jun 9, 2015

Methods of treating dyskinesia and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,312
App. No.
14/472,794
Granted
Jun 9, 2015
Kind
B2
Abstract

The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.

Claims (16)

1. A method of treating a dyskinesia in a human comprising administering to the human in need thereof an effective amount of sydnocarb, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the administration is oral.

3. The method of claim 1 wherein the human is administered a pharmaceutical composition comprising sydnocarb, or pharmaceutically acceptable salt thereof.

4. The method of claim 3 wherein the pharmaceutical composition is in the form of a tablet, pill, or capsule.

5. The method of claim 3 wherein 0.01 mg to 70 mg per kg body weight of sydnocarb is administered.

6. The method of claim 3 wherein 0.1 mg to 50 mg per kg body weight of sydnocarb is administered.

7. The method of claim 3 wherein 0.5 mg to 20 mg per kg body weight of sydnocarb is administered.

8. The method of claim 3 wherein the pharmaceutical composition further comprises another therapeutic agent.

9. The method of claim 8 wherein the another therapeutic agent is L-Dopa.

10. The method of claim 1 wherein the dyskinesia is levodopa-induced dyskinesia, chronic or tardive dyskinesia, or orofacial dyskinesia.

11. The method of claim 10 wherein the levodopa-induced dyskinesia is off-period dystonia, diphasic dyskinesia, or peak-dose dyskinesia.

12. The method of claim 1 wherein the sydnocarb comprises the formula

or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R 1 is H and r is 1; R 2 and R 3 are H and n is 1; R 4 and R 5 are H and p is 1; R 7 is H; and R 8 is H.

13. A method of treating levodopa-induced dyskinesia in a human comprising orally administering to the human in need thereof a pharmaceutical composition in the form of a tablet, pill, or capsule comprising 0.01 mg to 70 mg per kg body weight of sydnocarb comprising the formula

or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R 1 is H and r is 1; R 2 and R 3 are H and n is 1; R 4 and R 5 are H and p is 1; R 7 is H; and R 8 is H.

14. The method of claim 13 wherein the pharmaceutical composition further comprises L-Dopa.

Assignments (3)
SECURITY INTEREST Recorded Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2016
From: MELIOR DISCOVERY, INC.
To: MELIOR PHARMACEUTICALS II, LLC
Reel/Frame 038936/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2014
From: CIALLELLA, JOHN; GRUNER, JOHN; REAUME, ANDREW G.; SAPORITO, MICHAEL S.
To: MELIOR DISCOVERY, INC.
Reel/Frame 034115/0294 →